Dr. Patel emphasized the importance of early fertility preservation discussions before any cancer treatment begins. Personalized care, thorough counseling, and access to reproductive technologies are crucial for optimizing fertility outcomes in testicular cancer survivors. Addressing both medical and psychosocial factors enables patients to make informed decisions about their reproductive health.
Read More"Livestrong at the YMCA" offers a comprehensive approach to cancer recovery, combining personalized exercise with peer support to enhance physical and emotional well-being. The program helps survivors regain confidence, return to daily activities, and establish lifelong healthy habits within a supportive community.
Read MoreRoberts reiterated that these longstanding recommendations include eating a variety of foods, maintaining a healthy weight, limiting saturated fats, sugars, and sodium, and consuming alcohol in moderation. She stressed that these guidelines are applicable to cancer prevention, during treatment, and in survivorship.
Read MoreThey are conducting the Bridge Study, partnering with various cancer foundations, including the Testicular Cancer Awareness Foundation, to evaluate the effectiveness of these AI-generated summaries among patients with testicular cancer. Participants will compare original abstracts with AI-generated summaries to assess understandability, preference, and the time taken to comprehend the information.
Read MoreDr. Millard highlighted that pre-existing mental health issues can affect how patients cope with cancer. He shared the case of "Danny," a 28-year-old patient who refused chemotherapy despite a high cure rate for his condition, ultimately leading to his death.
Read MoreSleiter highlighted the importance of incorporating strategies to prevent ototoxicity into cancer treatment plans without compromising the effectiveness of chemotherapy.
Read MoreDr. Banegas emphasized that financial hardship is a multifaceted issue requiring a proactive and comprehensive approach from healthcare systems.
Read MoreAt the 2024 Testicular Cancer Conference presented by Fennec Pharmaceuticals, Dr. Timothy Masterson from Indiana University presented on the evolution of surgical management in metastatic testicular cancer. He traced the historical advancements from a time when there were no serum tumor markers, effective chemotherapy, or advanced imaging like CT scans. Early treatments involved extensive surgeries with high morbidity, and seminomas were primarily treated with radiation due to lower short-term risks compared to surgery.
Read MoreWe are excited to welcome John Klish (Klishy) as a guest speaker at the Testicular Cancer Conference 2018. John Klish was born with bi-lateral profound hearing loss, meaning profoundly deaf. That didn’t stop him from following his dreams. He graduated from Colorado State University with a degree in mechanical engineering while racing on the collegiate cycling team.
Read MoreWe are excited to welcome Tom Willner as a guest speaker at the Testicular Cancer Conference 2018. Tom Willner, President of Tom Willner Music and co-founder of Center Stage Education, is a musician, published songwriter, playwright, speaker, and author. He is a testicular cancer survivor who has written a musical and a book about his experience that raise awareness and funding for cancer charities, and teach healthcare professionals about the patient experience.
Read MoreWe are excited to welcome back Dr. Lawrence Einhorn as our honorary guest speaker, world renowned tc medical expert at our Testicular Cancer Conference 2018. Lawrence Einhorn, MD, has been on the IU School of Medicine Department of Medicine faculty since 1973. His field of expertise includes clinical trials and supportive care, with focus in the areas of lung and testicular cancers. Dr. Einhorn has also been involved in the clinical development of new drug therapies. Studies chaired by Dr. Einhorn at IU School of Medicine in testicular cancer led to the FDA approval of cisplatin, etoposide and ifosfamide. In addition, his groups conducted the pivotal studies that led to the approval of both gemcitabine and pemetrexed in non-small cell lung cancer. Dr. Einhorn’s studies helped to save many lives turning testicular cancer into a highly curable cancer with a 90% overall survival rate.
Read MoreWe are excited and honored to welcome back Dr. Ajay K. Nangia as a guest speaker at the Testicular Cancer Conference 2018. Dr. Ajay K. Nangia is Professor and Vice-Chair of Urology at the University of Kansas Medical Center. Dr. Nangia received his medical degree from St. Thomas and Guy's Hospital Medical School in London, U.K. He completed two years of research at Yale University prior to residency. He completed his Urology residency at the University of Pittsburgh Medical Center and a Male Infertility and Microsurgery fellowship at the Cleveland Clinic Foundation in Cleveland, Ohio. Dr. Nangia was at Dartmouth-Hitchcock Medical Center in New Hampshire prior to coming to Kansas. Dr. Nangia is a fellowship trained male infertility specialist in the metropolitan Kansas City area with 18 years of experience and national involvement in the field. He is one of the leading male infertility specialists nationally. He has extensive experience in male infertility, urological microsurgical reconstruction, including vasectomy reversals in the Kansas, Western Missouri, Oklahoma and Nebraska region. He also specializes in Men's Health issues as they relate to sexual and reproductive health, especially male contraception, testosterone deficiency, erectile dysfunction and ejaculatory problems. He and Dr. Broghammer have one of the largest practices in surgical correction for erectile dysfunction (penile prostheses) in the region. He also specializes in fertility and sexual dysfunction issues related to spinal cord injuries and pre- and post-cancer treatment. Dr. Nangia is a leading national specialist in the field of male infertility, vasectomy reversals, vasectomies and complications from vasectomies. He also has a secondary specialty in stone disease.
Read More
